Skip to Content

Alimera Sciences Inc ALIM

Morningstar Rating
$3.11 +0.16 (5.42%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ALIM is trading at a 142% premium.
Price
$2.94
Fair Value
$4.86
Uncertainty
Very High
1-Star Price
$6.12
5-Star Price
$4.86
Economic Moat
Vyw
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ALIM is a good fit for your portfolio.

Trading Information

Previous Close Price
$2.95
Day Range
$2.953.18
52-Week Range
$2.464.38
Bid/Ask
$3.11 / $3.28
Market Cap
$162.93 Mil
Volume/Avg
118,122 / 67,373

Key Statistics

Price/Earnings (Normalized)
Price/Sales
1.24
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East operations are managed as three operating segments: U.S., International and Operating Cost It generates maximum revenue from U.S. Segment.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Value
Total Number of Employees
158

Valuation

Metric
ALIM
Price/Earnings (Normalized)
Price/Book Value
4.33
Price/Sales
1.24
Price/Cash Flow
30.63
Price/Earnings
ALIM

Financial Strength

Metric
ALIM
Quick Ratio
2.13
Current Ratio
2.39
Interest Coverage
−0.97
Quick Ratio
ALIM

Profitability

Metric
ALIM
Return on Assets (Normalized)
−11.50%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
−6.09%
Return on Assets
ALIM
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - Specialty & Generic Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
MKKGY
Merck KGaA ADRTtpjhqgcnDpvpzj$78.9 Bil
ZTS
Zoetis Inc Class AZtbbzhrqdtSsnl$77.6 Bil
HLN
Haleon PLC ADRPmjktxhhMsxvs$37.6 Bil
TEVA
Teva Pharmaceutical Industries Ltd ADRJxjrpdsgWyyj$18.8 Bil
VTRS
Viatris IncVhzxkzqjJrpz$12.4 Bil
RDY
Dr Reddy's Laboratories Ltd ADRStcncqfmWgtqj$11.8 Bil
CTLT
Catalent IncChpmzwdtXvvxgn$9.9 Bil
PRGO
Perrigo Co PLCNwrxjhllCwglp$3.8 Bil
CURLF
Curaleaf Holdings IncHrlvtjfwJdyt$3.4 Bil
PBH
Prestige Consumer Healthcare IncTwkjmhmKmkgxg$3.2 Bil

Sponsor Center